Atlas market file · Equity · United States
Rallybio CorpRLYB
- Last close
- 16.19
- Change
- +0.31%
- 96-bar range
- 7.9 – 17.574
- As of
- 6 Aug 2026
Rallybio Corp is a pharmaceutical preparations issuer listed as RLYB on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
RLYB
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+79.09% over the window).
Source rail: Yahoo Finance chart API (RLYB). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for RLYB. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
RLYB public profile
Pharmaceutical preparations issuer. Rallybio Corp is connected to current market context, cited company sources and its retained research file.
Rallybio Corp trades as RLYB on NASDAQ. Rallybio Corp (RLYB) has a latest verified close of 16.19, up 0.31%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files RLYB under USA Stocks and Science & Biotech Stocks for browsing.
What changed for Rallybio Corp today
Rallybio Corp (RLYB) filed an S-4 on July 15, 2026, outlining plans for future clinical trials of RLYB116, including a confirmatory pharmacokinetic/pharmacodynamic study, while warning of potential safety risks post-approval. The biotech also announced a merger agreement with Avenzo Therapeutics in June, aiming to expand its oncology portfolio. Despite this strategic move, Rallybio’s latest 10-Q shows minimal revenue ($212,000) and a net loss of $8.3M for Q1 2026, with operating cash flow at -$8.0M.
The company’s core focus remains on complement dysregulation and hematology therapies, with RLYB116 (a C5 inhibitor) and RLYB332 (an anti-matriptase-2 antibody) in development. However, its pipeline has yet to generate commercial revenue, relying instead on dwindling cash reserves ($41.3M) and share issuance. The 10-Q reveals a weighted average of 5.7M diluted shares, raising concerns about dilution as insider transactions continue.
Financial strain is evident: liabilities are low ($4.2M), but stockholders’ equity ($50.3M) is eroded by consistent losses. R&D expenses ($2.9M) and capex further pressure cash, with no near-term revenue catalysts. The S-4 filing acknowledges trial competition and post-approval risks, while the Avenzo merger introduces integration uncertainties. Rallybio’s survival hinges on successful capital raises or partnership deals, given its 12-month burn rate.
Chart-wise, RLYB’s stock has no reported trading volume in the evidence, limiting technical analysis. The lack of liquidity and thin financials make it a speculative micro-cap play. The source directs readers to the Avenzo merger closure, RLYB116 trial timelines, and cash runway updates. Regulatory filings remain the primary source of material developments.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
RLYB technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on RLYB
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep RLYB research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
RLYB FAQ
What is Rallybio Corp (RLYB)?Rallybio Corp (RLYB) has a latest verified close of 16.19, up 0.31%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Rallybio Corp (RLYB) has a latest verified close of 16.19, up 0.31%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for RLYB?Rallybio Corp (RLYB) has a latest verified close of 16.19, up 0.31%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
Rallybio Corp (RLYB) has a latest verified close of 16.19, up 0.31%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files RLYB under USA Stocks and Science & Biotech Stocks for browsing.
How often is the RLYB page updated?The RLYB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The RLYB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for RLYB?The RLYB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:RLYB. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The RLYB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:RLYB. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on RLYB?Yes. The workstation can open RLYB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open RLYB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this RLYB page investment advice?No. The RLYB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The RLYB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →